By: IPP Bureau
Last updated : April 11, 2025 10:34 am
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced that the US Food and Drug Administration (USFDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. Jobevne, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab).
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor.
The approval of Jobevne expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes Ogivri (Trastuzumab-dkst) and Fulphila (Pegfilgrastim-jmdb). The company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name Abevmy.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. said, “The USFDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.”
In the US, sales of bevacizumab were approximately $2 billion in 2023.
The approval for Jobevne (bevacizumab-nwgd) was based on a comprehensive package of comparative pharmacokinetic, safety, efficacy, nonclinical, structural, analytical and functional data, which confirmed that Jobevne is highly similar to Avastin (bevacizumab).
The data demonstrated that there were no clinically meaningful differences between Jobevne and Avastin in terms of pharmacokinetics, safety, efficacy, and immunogenicity.